NOVOCURE LTD (NVCR) Stock Price, Forecast & Analysis
USA - NASDAQ:NVCR - JE00BYSS4X48 - Common Stock
NVCR Key Statistics, Chart & Performance
The current stock price of NVCR is 10.92 USD. In the past month the price decreased by -19.05%. In the past year, price decreased by -37.39%.
NVCR Latest News, Press Relases and Analysis
NVCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 69.98 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About NVCR
Company Profile
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Company Info
NOVOCURE LTD
No. 4 The Forum, Grenville Street
Saint Helier JE2 4UF JE
CEO: Asaf Danziger
Employees: 1488
Phone: 441534756700
NOVOCURE LTD / NVCR FAQ
What does NVCR do?
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
What is the current price of NVCR stock?
The current stock price of NVCR is 10.92 USD. The price decreased by -3.11% in the last trading session.
What is the dividend status of NOVOCURE LTD?
NVCR does not pay a dividend.
How is the ChartMill rating for NOVOCURE LTD?
NVCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for NOVOCURE LTD?
NOVOCURE LTD (NVCR) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Should I buy NVCR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVCR.
NVCR Technical Analysis
NVCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCR. NVCR has a bad profitability rating. Also its financial health evaluation is rather negative.
NVCR Financial Highlights
Over the last trailing twelve months NVCR reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.15% | ||
| ROE | -45.36% | ||
| Debt/Equity | 1.81 |
NVCR Forecast & Estimates
14 analysts have analysed NVCR and the average price target is 27.48 USD. This implies a price increase of 151.61% is expected in the next year compared to the current price of 10.92.
For the next year, analysts expect an EPS growth of 8.25% and a revenue growth 8.49% for NVCR